$AUTL Trend Reversal - LONG
8M Float
8% Short
$386 M market cap
Offering complete Feb 12
Looks like AUTL may be breaking out of it's downtrend soon. I picked up a position on Feb 12.
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Autolus Therapeutics today and set a price target of $18.00. The company’s shares closed last Friday at $7.29.
According to TipRanks.com, Goldstein is a 5-star analyst with an average return of 19.4% and a 43.5% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals.
Currently, the analyst consensus on Autolus Therapeutics is a Strong Buy with an average price target of $16.20. (source: smarteranalyst.com/new-blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-autolus-therapeutics-autl-denali-therapeutics-dnli-and-viatris-vtrs/)
8% Short
$386 M market cap
Offering complete Feb 12
Looks like AUTL may be breaking out of it's downtrend soon. I picked up a position on Feb 12.
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Autolus Therapeutics today and set a price target of $18.00. The company’s shares closed last Friday at $7.29.
According to TipRanks.com, Goldstein is a 5-star analyst with an average return of 19.4% and a 43.5% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals.
Currently, the analyst consensus on Autolus Therapeutics is a Strong Buy with an average price target of $16.20. (source: smarteranalyst.com/new-blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-autolus-therapeutics-autl-denali-therapeutics-dnli-and-viatris-vtrs/)
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.